Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implications for clinical trials

Journal of the American College of Cardiology

Volumn 33, Issue 7, 1999, Pages 1935-1942

  Dibbs, Ziad ^c   Thornby, John ^c   White, B G ^a   Mann, Douglas L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Clinical Cardiovascular Research   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; CLINICAL TRIALS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032745559     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00130-8     Document Type: Article

References (42)

1. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure . J Am Coll Cardiol. 20:1992;248-254.
2. Seta Y., Shan K., Bozkurt B., et al. Basic mechanisms in heart failure the cytokine hypothesis . J Card Failure. 2:1996;243-249.
3. Suffredini A.F., Fromm R.E., Parker M.M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 321:1989;280-287.
4. Millar A.B., Singer M., Meager A., et al. Tumor necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet. 2:1989;712-713.
5. Hegewisch S., Weh H.J., Hossfeld D.K. TNF-induced cardiomyopathy. Lancet. 2:1990;294-295.
6. Mohler E.R.I., Sorensen L.C., Ghali J.K., et al. Role of cytokines in the mechanism of action of amlodipine the PRAISE heart failure trial . J Am Coll Cardiol. 30:1997;35-41.
7. Goldstein D.J., Moazami N., Seldomridge J.A., et al. Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. Ann Thorac Surg. 63:1997;971-974.
8. Milani R.V., Mehra M.R., Endres S., et al. The clinical relevance of circulating tumor necrosis factor-α in acute decompensated chronic heart failure without cachexia. Chest. 110:1996;992-997.
9. Deng M.C., Erren M., Lutgen A., et al. Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int J Cardiol. 57:1996;129-134.
10. Sliwa K., Skudicky D., Candy G., et al. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093.
11. Deswal A., Seta Y., Blosch C.M., Mann D.L. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure. (abstr) Circulation. 96:1997;I1802.
12. Dutka D.P., Elborn J.S., Delamere F., et al. Tumour necrosis factor-alpha in severe congestive cardiac failure. Br Heart J. 70:1993;141-143.
13. Masson S., Latini R., Bevilacqua M., et al. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res. 37:1998;213-217.
14. Torre-Amione G., Kapadia S., Benedict C.R., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the studies of left ventricular dysfunction (SOLVD) . J Am Coll Cardiol. 27:1996;1201-1206.
15. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92:1995;1487-1493.
16. Cannon J.G., Nerad J.L., Poutsiaka D.D., Dinarello C.A. Measuring circulating cytokines. J Appl Physiol. 75:1993;1897-1902.
17. Bozkurt B., Shan K., Seta Y., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in human heart failure. Heart Failure Rev. 1:1996;211-219.
18. Wiedermann C.J., Beimpold H., Herold M., et al. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol. 22:1993;1897-1901.
19. Katz S.D., Rao R., Berman J.W., et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure relation to nitric oxide-dependent vasodilation in the forearm circulation . Circulation. 90:1994;12-16.
20. Munger M.A., Johnson B., Amber I.J., et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 77:1996;723-727.
21. Mohler K.M., Torrance D.S., Smith C.A., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151:1993;1548-1561.
22. Novick D., Shulman L.M., Chen L., Revel M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine. 4:1992;6-11.
23. Rosenson R.S., Tangney C.C., Hafner J.M. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb. 14:1994;1928-1932.
24. Woolson R.F. Statistical Methods for the Analysis of Biomedical Data. 1987;23-24 John Wiley, New York.
25. Benedict C.R., Johnstone D.E., Weiner D.H., et al. Relation of neurohormonal activation to clinical variables and degree of ventricular dysfunction a report from the registry of studies of left ventricular dysfunction . J Am Coll Cardiol. 23:1994;1410-1420.
26. Sindhwani R., Yuen J., Hirsch H., et al. Reversal of low flow state attenuates immune activation in severe decompensated congestive heart failure. (abstr) Circulation. 88:1993;I255.
27. Sothern R.B., Roitman-Johnson B., Kanabrocki E.L., et al. Circadian characteristics of circulating interleukin-6 in men. J Allergy Clin Immunol. 95:1995;1029-1035.
28. Young M.R., Matthews J.P., Kanabrocki E.L., et al. Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor in men. Chronobiol Int. 12:1995;19-27.
29. Aderka D., Engelmann H., Maor Y., et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323-329.
30. Peters M., Jacobs S., Ehlers M., et al. The function of the soluble interleukin6 (IL-6) receptor in vivo sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6 . J Exp Med. 183:1996;1399-1406.
31. Ndubuisi M.I., Patel K., Rayanade R.J., et al. Distinct classes of chaperoned IL-6 in human blood differential immunological and biological availability . J Immunol. 160:1998;494-501.
32. Joyce D.A., Steer J.H. Tumor necrosis factor alpha and interleukin-1 alpha stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes. J Interferon Cytokine Res. 15:1995;947-954.
33. Frieling J.T., Van Deuren M., Wijdenes J., et al. Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis. 171:1995;469-472.
34. Hisano S., Sakamoto K., Ishiko T., et al. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field. Cytokine. 9:1997;447-452.
35. Angelis P., Scharf S., Mander A., et al. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci Lett. 244:1998;106-108.
36. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
37. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation. 92:1995;1479-1486.
38. Stefenelli T., Bergler-Klein J., Globits S., et al. Heart rate behavior at different stages of congestive heart failure. Eur Heart J. 13:1992;902-907.
39. Gibelin P., Robillon J.F., Candito M., et al. Nocturnal-diurnal changes of norepinephrine blood levels in patients with chronic cardiac insufficiency. Ann Cardiol Angeiol (Paris). 41:1992;321-325.
40. Yoshino F., Sakuma N., Date T., et al. Diurnal change of plasma atrial natriuretic peptide concentrations in patients with congestive heart failure. Am Heart J. 117:1989;1316-1319.
41. Casolo G., Balli E., Fazi A., et al. Twenty-four-hour spectral analysis of heart rate variability in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 67:1991;1154-1158.
42. Francis G.S., Goldsmith S.R., Ziesche S.M., Cohn J.N. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol. 49:1982;1152.